VOR — Vor Biopharma Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1817229 ·
Last close
$18.52
Market Cap
$1.10B
52W High
$49.95
52W Low
$6.50
ADV30
1,084,497
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -47,853,000 | -62,810,000 | 481,053,000 | 107,855,000 | 681,250,000 |
| Mar 2026 | 0 | — | -35,160,000 | -219,585,000 | 506,746,000 | 169,873,000 | 657,170,000 |
| Dec 2025 | 0 | — | -35,960,000 | 1,722,858,000 | 464,126,000 | 396,486,000 | 628,438,000 |
| Sep 2025 | 0 | — | -28,107,000 | -812,684,000 | 176,237,000 | 160,462,000 | 2,401,724,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-149,893,000
Investing CF
$-311,809,000
Financing CF
$579,283,000
CapEx
$-758,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-383.15
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,372,560,000
Inventory
—
Receivables
—
ST Investments
$321,652,000
EBIT TTM
$-373,511,000
Pretax Income TTM
$-883,080,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -371,642,000 | -695,981,000 | 464,126,000 | 628,438,000 | -164,312,000 | -142,713,000 |
| Dec 2024 | 0 | -121,185,000 | -116,914,000 | 142,891,000 | 46,227,000 | 96,664,000 | -99,660,000 |
| Dec 2023 | 0 | -126,036,000 | -117,863,000 | 198,126,000 | 47,402,000 | 150,724,000 | -100,292,000 |
| Dec 2022 | 0 | -93,418,000 | -92,094,000 | 299,366,000 | 48,759,000 | 250,607,000 | -85,144,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.81
Max Pain — expiry 2027-02-19
max pain strike: $20.00 · spot: $18.62 · call oi: 2,615 · put oi: 309
Expected Move to 2027-02-19:
±$8.45
(45.38%) —
implied range
$10.17 –
$27.07
· ATM straddle on $17.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MGTX | MeiraGTx Holdings plc | $1.05B | $10.91 | — |
| REPL | Replimune Group, Inc. | $1.16B | $12.36 | — |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.00B | $11.77 | — |
| ODTX | Odyssey Therapeutics, Inc. | $985.68M | $20.51 | — |
| IMTX | Immatics N.V. | $1.27B | $8.37 | — |
News headlines (Yahoo Finance, 1h cache)
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
2026-09-08 11:00 · Yahoo
Vor Bio To Participate in Upcoming September Conferences
2026-09-01 12:00 · Yahoo
Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next
2026-06-30 15:08 · Yahoo
We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely
2026-05-15 12:25 · Yahoo
Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade
2026-05-07 13:55 · Yahoo
Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies |
2026-09-16 14:31 · Yahoo
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-11 13:30 · Yahoo
Vor Bio Appoints David Zaccardelli to Board of Directors
2026-07-07 20:01 · Yahoo
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 21:30 · Yahoo
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-28 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.